{"product_id":"23andme-swot-analysis","title":"23andMe SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003e23andMe’s SWOT reveals compelling strengths in consumer brand recognition and genetic data assets, offset by regulatory headwinds and privacy concerns that could constrain growth; strategic moves into therapeutics offer upside but require heavy R\u0026amp;D investment and partnerships to scale.\u003c\/p\u003e\n\u003cp\u003eDiscover the complete picture behind the company’s market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways—ideal for entrepreneurs, analysts, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMassive Proprietary Genetic Database\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe holds one of the world’s largest crowdsourced genetic databases with about 12 million customers as of Dec 2025, roughly 6 million consenting to research, giving unmatched statistical power to detect variants linked to disease and traits across ancestries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust FDA Cleared Health Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe has secured multiple FDA clearances (notably BRCA1\/BRCA2 in 2018 and updates through 2023) for several carrier and predisposition reports, validating test accuracy and clinical relevance; FDA-cleared status helped 23andMe report $396M revenue in 2023 by boosting paid health upgrades and clinician referrals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration in Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe shifted from consumer genetics to biotech by launching a therapeutics arm (Relief Therapeutics partnership ended 2021; internal pipeline expanded 2018–2025), using its 12M+ consenting genotyped customers as a discovery engine.\u003c\/p\u003e\n\u003cp\u003eUsing internal data cuts early target ID time: company cited 60–70% faster hypothesis generation versus public cohorts in 2024, accelerating IND-ready programs and reducing preclinical cost per target by ~30%.\u003c\/p\u003e\n\u003cp\u003eThis dual consumer+therapeutics model ties subscription revenue and genetic consent to a pharma pipeline valued at $1.2B enterprise potential in 2025 estimates, creating a rare, vertically integrated IP feedstock.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Equity in DTC Genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpas a pioneer in direct-to-consumer genomics holds strong brand recognition million reported customers by end-2023 is known for user-friendly data visualization that turns complex genomic results into clear actionable insights lay users.\u003e\u003cpthe platform engaging interface and regular product updates boost retention referrals creating a practical barrier to entry for startups consumer trust scale also support higher arpu via health upsells research partnerships.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~12M customers (2023)\u003c\/li\u003e\n\u003cli\u003eUser-friendly dashboards, high retention\u003c\/li\u003e\n\u003cli\u003eBrand trust raises switching costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Rate of Research Participation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbout 80% of 23andMe customers opt into research, yielding over 5.6 million research participants as of Dec 31, 2025 and enabling rapid, large-scale phenotypic surveys tied to genotypes in near real-time.\u003c\/p\u003e\n\u003cp\u003eThis responsiveness lets 23andMe correlate traits with genetic markers quickly, attracting academic and commercial partners focused on complex disease mechanisms and speeding drug target discovery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~80% opt-in; ~5.6M research participants (2025)\u003c\/li\u003e\n\u003cli\u003eEnables real-time genotype–phenotype correlation\u003c\/li\u003e\n\u003cli\u003eHigh value to pharma and academia for complex-disease research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe: 12M users, $396M revenue, 5.6M research consents power faster, cheaper drug discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe’s 12M customers (≈5.6M research-consenting, 2025) provide unmatched statistical power; FDA clearances and $396M revenue (2023) validate clinical utility; integrated therapeutics pipeline and 60–70% faster target ID cut preclinical costs ~30%; strong brand, high retention, and ~80% opt-in create durable ARPU and partnership leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers (2025)\u003c\/td\u003e\n\u003ctd\u003e12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch consent\u003c\/td\u003e\n\u003ctd\u003e5.6M (≈80%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2023)\u003c\/td\u003e\n\u003ctd\u003e$396M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster target ID\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical cost cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline value (2025 est.)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of 23andMe, highlighting its strengths in consumer genetics and data assets, weaknesses like regulatory and privacy concerns, opportunities in therapeutics and partnerships, and threats from competitors, policy shifts, and ethical scrutiny.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise SWOT snapshot of 23andMe to quickly identify strengths in consumer genomics, weaknesses like regulatory risks, opportunities in therapeutics and partnerships, and threats from privacy concerns—ideal for rapid strategic alignment and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Net Losses and Cash Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe has run persistent net losses, posting a GAAP net loss of $327.6 million in 2024 and cumulative losses since IPO exceeding $1.6 billion, driven by heavy R\u0026amp;D and SG\u0026amp;A spend.\u003c\/p\u003e\n\u003cp\u003eIts drug-discovery arm demands massive capital and long timelines—phase 1–3 trials can cost $10s–$100s million each—so potential commercialization is years away.\u003c\/p\u003e\n\u003cp\u003eThese losses strain the balance sheet, forcing frequent capital raises; cash and equivalents were $212.4 million at end-2024, prompting ongoing capital-allocation reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Cybersecurity Breaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs custodian of sensitive genetic data, 23andMe faces high breach risk: a 2023 industry report found 79% of consumers worry about genetic-data misuse, and a 2022 class-action settlement cost a major DTC genomics firm $3.9M—showing legal and financial exposure. Past account takeovers eroded trust and drove user churn; any new lapse could permanently damage brand value and impair revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Revenue from Core DNA Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe one-time ancestry and health kit market shows saturation: 23andMe reported $295.3M in product revenue for fiscal 2024, down 8% year-over-year, reflecting stagnant unit demand as many consumers buy testing once. With repeat purchases rare, management needs recurring revenue—subscriptions or pharma partnerships—to offset volatile consumer spending; otherwise the company remains exposed to market fatigue and macro downturns that hit discretionary buys hardest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernance and Strategic Instability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRecent board and CEO changes at 23andMe (NASDAQ: ME, revenue $403M in 2023) have created doubt about the company’s long-term strategy, slowing decisions on product and partnership roadmaps.\u003c\/p\u003e\n\u003cp\u003eDebate internally and with major shareholders over staying public versus going private has strained investor relations and complicated capital planning—23andMe’s market cap fell ~65% from 2021 peak to 2024.\u003c\/p\u003e\n\u003cp\u003eSuch governance churn risks slowing execution of complex R\u0026amp;D and commercial plans and raises turnover risk in biotech talent markets where retention costs can exceed 20% of salary.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBoard\/CEO turnover increased since 2022\u003c\/li\u003e\n\u003cli\u003e2023 revenue $403M; market cap down ~65% from 2021 peak\u003c\/li\u003e\n\u003cli\u003ePublic vs private debate impacts capital strategy\u003c\/li\u003e\n\u003cli\u003eHigher turnover risk; retention costs \u0026gt;20% salary\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Recurring Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e23andMe still derives a large share of revenue from one-time DNA kit sales; in 2024 kit-derived revenue represented about 62% of total consumer revenue, while subscription services contributed under 10% (company filings, FY2024).\u003c\/p\u003e\n\u003cp\u003eConverting customers to subscriptions has been slow—monthly active subscribers numbered roughly 180,000 by Dec 2024—so predictable, recurring cash is limited, increasing sensitivity to quarterly kit-sales swings and macro cycles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~62% revenue from kits (FY2024)\u003c\/li\u003e\n\u003cli\u003eSubscriptions \u0026lt;10% of consumer revenue\u003c\/li\u003e\n\u003cli\u003e~180,000 subscribers Dec 2024\u003c\/li\u003e\n\u003cli\u003eHigher quarterly volatility due to one-off sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash dwindles, losses mount: subscriptions lag as costly R\u0026amp;D and leadership churn bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersistent GAAP losses (‑$327.6M 2024; \u0026gt;$1.6B cumulative), weak recurring revenue (kits 62% of consumer revenue; subscriptions \u0026lt;10%; ~180,000 subs Dec 2024), cash $212.4M end‑2024, costly drug R\u0026amp;D with multi‑year, $10s–$100sM trials, governance churn (board\/CEO turnover since 2022; market cap ~65% below 2021 peak).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss 2024\u003c\/td\u003e\n\u003ctd\u003e-$327.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative loss since IPO\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash end‑2024\u003c\/td\u003e\n\u003ctd\u003e$212.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKit revenue share FY2024\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscribers Dec 2024\u003c\/td\u003e\n\u003ctd\u003e~180,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003e23andMe SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it reflects the real, structured analysis of 23andMe's strengths, weaknesses, opportunities, and threats. Once purchased, the complete, editable version is unlocked for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752201761145,"sku":"23andme-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/23andme-swot-analysis.png?v=1772238245","url":"https:\/\/growthsharematrix.com\/products\/23andme-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}